Eli Lilly I1F-MC-RHAZ
Laufzeit: 01.01.2012 - 31.12.2018
imported
Kurzfassung
A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis